ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Efficacy and safety of intravitreal faricimab for choroidal neovascularization secondary to central serous chorioretinopathy - a multicentre study.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAssess real-world efficacy and safety of intravitreal faricimab in the management of central serous chorioretinopathy (CSCR) associated choroidal neovascularization (CNV).
methodsIn this multicenter retrospective study, Patients receiving one or more intravitreal faricimab injections for CSCR-associated CNV were included. Subgroup analysis involved both treatment-naïve individuals and those switched from prior anti-VEGF agents. Clinical and anatomical parameters including best-recorded visual acuity (BRVA), central macular thickness (CMT), subfoveal choroidal thickness (SFCT), neurosensory detachment (NSD), and pigment epithelial detachment (PED) height-were assessed at baseline and at one month after the first and third injections. Treatment response was categorized as complete resolution (absence of subretinal fluid [SRF]/intraretinal fluid [IRF]), optimal (> 50% SRF reduction or subjective IRF improvement), or suboptimal(no improvement/worsening) response.
resultsA total of 42 eyes (40 patients) across six centers were included. Mean age was 62.38 ± 9.48 years and 62.5% were males. Nineteen eyes were treatment-naïve, while 23 had received prior anti-VEGF therapy. Mean BCVA improved significantly from 0.78 ± 0.41 to 0.59 ± 0.35 logMAR after the first dose (p < 0.001), and from 0.71 ± 0.43 to 0.59 ± 0.57 logMAR following the third dose (p = 0.011). Significant reductions in CMT, SFCT, and NSD height were observed post-treatment; however, PED height did not change significantly. Similar results were seen in both subgroups after the first injection. Complete SRF resolution was achieved in 43% of eyes, with 45.7% showing optimal and 11.4% suboptimal response. One patient developed bilateral anterior uveitis after the third injection, which resolved with topical corticosteroids.
conclusionIntravitreal faricimab appears to be a safe and effective option for CSCR-associated CNV, demonstrating anatomical and functional improvements, particularly in cases with unresponsive to prior anti-VEGFs.
Indexed as
Identifiers
41204995What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.